Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Trastuzumab-rezetecan”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Testing effectiveness (Phase 2)Looking for participantsNCT07704177
What this trial is testing

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer

Who this might be right for
Biliary Tract Neoplasms Immunotherapy
Peking Union Medical College Hospital 70
Testing effectiveness (Phase 2)Looking for participantsNCT07741448
What this trial is testing

Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC

Who this might be right for
UTUC
Zhiquan Hu 54
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07778745
What this trial is testing

A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC

Who this might be right for
NSCLC
Tianjin Medical University Cancer Institute and Hospital 37
Testing effectiveness (Phase 2)Looking for participantsNCT07309770
What this trial is testing

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

Who this might be right for
Urachal CancerAdvanced Solid Tumor CancerAntibody-drug Conjugates
Sheng Zhang 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07796763
What this trial is testing

A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2

Who this might be right for
Advanced Colorectal Cancer Expressing HER2
Jiangsu HengRui Medicine Co., Ltd. 48
Testing effectiveness (Phase 2)Looking for participantsNCT07616453
What this trial is testing

Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer

Who this might be right for
HR+/HER2- Early Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07630077
What this trial is testing

Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities

Who this might be right for
Non Small Cell Lung Cancer
Sun Yat-sen University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07699952
What this trial is testing

First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations

Who this might be right for
Lung Cancer (NSCLC)EGFR Activating MutationHER2
Yongsheng Wang 35
Not applicableActive Not RecruitingNCT07387874
What this trial is testing

A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors

Who this might be right for
Recurrent or Metastatic Solid Tumors
Lixiaoling 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07317778
What this trial is testing

Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)HR Positive/HER2 Low Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 249
Testing effectiveness (Phase 2)Looking for participantsNCT07241793
What this trial is testing

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

Who this might be right for
Urothelial CarcinomaAdvanced Urothelial CarcinomaUrothelial Carcinoma Recurrent
Sun Yat-sen University 96
Early research (Phase 1)Not Yet RecruitingNCT07581574
What this trial is testing

Neoadjuvant SHR-A1811 and SHR-A1701 for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 12
Testing effectiveness (Phase 2)Looking for participantsNCT07647263
What this trial is testing

Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
The First Affiliated Hospital of Soochow University 124
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07639983
What this trial is testing

Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma

Who this might be right for
Muscle-Invasive Bladder Cancer (MIBC)Urinary Bladder Cancer
Sheng Tai 44
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07716111
What this trial is testing

Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 24
Large-scale testing (Phase 3)Looking for participantsNCT07679360
What this trial is testing

Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 1,000
Post-approval studies (Phase 4)Looking for participantsNCT07600164
What this trial is testing

Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer

Who this might be right for
HER2 + Breast CancerAdvanced Breast Cancer
Peking University People's Hospital 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07179939
What this trial is testing

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Who this might be right for
HER2-positive Breast Cancer
Fudan University 288
Testing effectiveness (Phase 2)Looking for participantsNCT07340398
What this trial is testing

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07836543
What this trial is testing

Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Ming Chen 105
Next Page